Estrogen action and prostate cancer

References

• Huggins C, Hodges CV. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1, 293–297 (1941).
   Google Scholar
• Huggins C. Endocrine control of prostate cancer. Science97, 541–544 (1943).
   PubMedGoogle Scholar
• Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J. Urol.185, 17–23 (2010).
   PubMedGoogle Scholar
• Citrin DL, Resnick MI, Guinan P et al. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. Prostate18, 139–146 (1991).
   PubMed Web of Science ®Google Scholar
• Dal Pra A, Cury FL, Souhami L. Combining radiation therapy and androgen deprivation for localized prostate cancer – a critical review. Curr. Oncol.17(5), 28–38 (2010).
   PubMedGoogle Scholar
• Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr. Opin. Support Palliat. Care4(3), 147–152 (2010).
   PubMedGoogle Scholar
• Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inibits the telemorase activity and gene expression of prostate cancer cells. Prostate70, 1307–1312 (2010).
   PubMedGoogle Scholar
• Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Vorey E. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer10, 244 (2010).
   PubMedGoogle Scholar
• Post-menopausal estrogen therapy. IARC Mongr. Eval. Carcinog. Risks Hum.72, 399–530 (1992).
   Google Scholar
• International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. IARC, Lyon, France, 7, 280–285 (1987).
   Google Scholar
• International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and postmenopausal hormone therapy. IARC, Lyon, France, 72 (1999).
   Google Scholar
• Greenwald P, Caputo TA, Wolfgang PE. Endometrial cancer after menopausal use of estrogens. Obstet. Gynecol.50, 239–243 (1977).
   PubMed Web of Science ®Google Scholar
• Siiteri PK, Nisker JA, Hammond GL. Hormonal basis of risk factors for breast and endometrial cancer. In: Hormones and Cancer. Iacobelli S, King RJB, Lindner HR, Lippman ME (Eds). Raven Press, NY, USA, 499–505 (1980).
   Google Scholar
• Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis17, 2279–2284 (1996).
   PubMed Web of Science ®Google Scholar
• Bernstein L. The epidemiology of breast cancer. LOWAC J.1, 7–13 (1998).
   Google Scholar
• Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res.50(1), 169–173 (1990).
   PubMed Web of Science ®Google Scholar
• Modugno F, Weissfeld JL, Trump DL et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin. Cancer Res.7, 3092–3096 (2001).
   PubMedGoogle Scholar
• Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst.88, 1118–1126 (1996).
   PubMed Web of Science ®Google Scholar
• Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer80, 930–934 (1999).
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Rifai N et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev.14, 1262–1269 (2005).
   PubMed Web of Science ®Google Scholar
• Wiren S, Stocks T, Rinaldi S, Hallmans G et al. Androgens and prostate cancer risk: a prospective study. Prostate67, 1230–1237 (2007).
   PubMedGoogle Scholar
• Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res.10, 440–448 (2004).
   PubMed Web of Science ®Google Scholar
• Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab.89, 2431–2441 (2004).
   Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68, 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor α signalling. FASEB J.22, 1512–1520 (2008).
   PubMed Web of Science ®Google Scholar
• Cussenot O, Azzouzi AR, Nicolaiew N et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol.25, 3596–3602 (2007).
   PubMedGoogle Scholar
• John K, Ragavan N, Pratt MM et al. Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate. Prostate69(5), 505–519 (2009).
   PubMed Web of Science ®Google Scholar
• Ragavan N, Hewitt R, Cooper LJ et al. CYPB1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett.215(1), 69–78 (2004).
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Nelson WG, Rifai N. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J. Clin. Endocrinol. Metab.92(7), 2519–2525 (2007).
   PubMed Web of Science ®Google Scholar
• Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br. J. Cancer57, 216–218 (1988).
   PubMed Web of Science ®Google Scholar
• Powell IJ, Meyskens FL Jr. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology57, 178–181 (2001).
   PubMedGoogle Scholar
• Ho SM, Roy D. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett.84, 155–162 (1994).
   PubMed Web of Science ®Google Scholar
• Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl Cancer Inst.80, 1045–1053 (1988).
   PubMedGoogle Scholar
• Bosland MC, Ford H, Horton L. Induction of a high incidence of ductal prostate adenocarcinoma in NBL and Sprague Dawley rats treated with estrdaiol-17β or diethylstilbestrol in combination with testosterone. Carcinogenesis16, 1311–1317 (1995).
   PubMed Web of Science ®Google Scholar
• Bosland MC. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev. Urol.7(3), S4–S10 (2005).
   Google Scholar
• Arai Y, Chen CY, Nishizuka Y. Cancer development in male reproductive tract in rats given diethylstilbestrol at neonatal age. Gann.69(6), 861–862 (1978).
   PubMedGoogle Scholar
• McLachlan JA, Newbold RR, Li S, Negishi M. Are estrogens carcinogenic during development of the testes? APMIS106, 240–244 (1998).
   PubMedGoogle Scholar
• Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann. NY Acad. Sci.1089, 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Rep. Toxicol.23(3), 374–382 (2007).
   PubMed Web of Science ®Google Scholar
• Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev.4, 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Miki J, Rhim J. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis.11, 32–39 (2008).
   PubMedGoogle Scholar
• Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original tumor in vivo. Cancer Res.67, 4708–4715 (2007).
   Google Scholar
• Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single cell. Nature456, 804–808 (2008).
   PubMed Web of Science ®Google Scholar
• Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res.68, 9703–9711 (2008).
   PubMedGoogle Scholar
• Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl.2, 33–50 (1989).
   PubMedGoogle Scholar
• Lang SH, Stark M, Collins A et al. Experimental prostate morphogenesis in response to stroma and three dimensional matrigel culture. Cell Growth Differ.12, 631–640 (2001).
   PubMedGoogle Scholar
• Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl Acad. Sci. USA105, 20882–20887 (2008).
   PubMed Web of Science ®Google Scholar
• Garraway IP, Sun W, Tran CP et al. Human prostate sphere-forming cells represent a subset of basall epithelial cells capable of glandular regeneration in vivo. Prostate40, 491–501 (2010).
   Google Scholar
• Hu WY, Shi GB, Hu DP et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology DOI: 10.1210/en.2010-1377 (2011) (Epub ahead of print).
   Google Scholar
• Taylor RA, Cowin PA, Cunha GR et al. Formation of human prostate tissue from embryonic stem cells. Nat. Methods3, 179–181 (2006).
   PubMed Web of Science ®Google Scholar
• Titus-Emstoff L, Hatch EE, Hoover RN et al. Long term risk in women given diethylstilbestrol (DES) during pregnancy. Br. J. Cancer84, 126–133 (2001).
   PubMedGoogle Scholar
• Colton T, Greenberg ER, Noller K et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. Further follow-up. JAMA269, 2096–2100 (1993).
   PubMed Web of Science ®Google Scholar
• Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternial stilbestrol therapy with tumor appearance in women. N. Engl. J. Med.284, 878–881 (1971).
   PubMed Web of Science ®Google Scholar
• Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE. Prenatal exposure to stibestrol. A prospective comparison of exposed female offspring with unexposed controls. N. Engl. J. Med.292, 334–339 (1976).
   Google Scholar
• Palmer JR, Wise LA, Hatch EE et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol. Biomark. Prev.15, 1509–1514 (2006).
   PubMed Web of Science ®Google Scholar
• Driscoll SG, Taylor SH. Effects of the prenatal maternal estrogen on the male urogenital system. Obstet. Gynecol.56, 537–542 (1980).
   PubMedGoogle Scholar
• Ekbom A, Wuu J, Adami HO et al. Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol. Biomarkers Prev.9, 221–223 (2000).
   PubMedGoogle Scholar
• Prins GS, Birch L, Habermann H et al. Influence of neonatal estrogens on rat prostate development. Reprod. Fertil. Dev.13, 241–252 (2001).
   PubMedGoogle Scholar
• Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J. Androl.25, 330–337 (2004).
   PubMedGoogle Scholar
• Prins GS. Developmental estrogenization of the prostate gland. In: Prostate: Basic and Clinical Aspects. Naz RK (Ed.). CRC Press, FL, USA, 247–265 (1997).
   Google Scholar
• Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17B or dietlhylstilbestrol. Carcinogenesis16, 1311–1317 (1995).
   PubMed Web of Science ®Google Scholar
• Ho SM, Wang WY, Belmonte J, Prins GS. Developmental exposure estradiol and bisphenol A (BPA) increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodisesterase type 4 variant (PDE4D4) in the rat prostate. Cancer Res.66, 5624–5632 (2006).
   PubMed Web of Science ®Google Scholar
• Prins GS, Ye SH, Birch L, Ho SM, Kannan K. Serum bisphenol A pharmacokinetics and prostatic responses following oral and subcutaneous exposures in neonatal sprague-dawley rats. Reprod. Toxicol.31(1), 1–9 (2011).
   PubMed Web of Science ®Google Scholar
• Prins GS, Ho SM. Early life estrogens and prostate cancer in an animal model. J. Dev. Orig. Health Dis.1, 365–370 (2010).
   PubMedGoogle Scholar
• Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol.45, 629–656 (2005).
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev.7, 21–33 (2006).
   Google Scholar
• Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res.64, 1975–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Enokida H, Shiina H, Urakami S et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res.11, 6582–6588 (2005).
   PubMed Web of Science ®Google Scholar
• Vardi A, Bosviel R, Rabiau N et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo24(4), 393–400 (2010).
   PubMed Web of Science ®Google Scholar
• Majid S, Dar AA, Shahryari V et al. Genistein reverses hypermethylation and induces active histone modifications in tumor-suppressor gene B-cell translocation gene 3 in prostate cancer. Cancer116(1), 66–76 (2010).
   PubMed Web of Science ®Google Scholar
• Kikuno N, Shiina H, Urakami S et al. Genistein mediated histone acetylation and demethylation activates tumor-suppressor genes in prostate cancer cells. Int. J. Cancer123(3), 552–560 (2008).
   PubMed Web of Science ®Google Scholar
• Li S, Washburn KA, Moore R et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactorfferrin gene in mouse uterus. Cancer Res.57, 4356–4359 (1997).
   PubMed Web of Science ®Google Scholar
• Alworth LC, Howdeshell KL, Ruhlen RL et al. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. Toxicol. Appl. Pharmacol.183, 10–22 (2002).
   PubMed Web of Science ®Google Scholar
• Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disuptors and male fertility. Science308, 1466–1469 (2005).
   PubMed Web of Science ®Google Scholar
• Lang R, Redmann U. Non-mutagenicity of some sex hormones in the salmonella/microsome mutagenicity test. Mutat. Res.67, 361– 365 (1979).
   PubMedGoogle Scholar
• Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem.24, 353–356 (1986).
   PubMedGoogle Scholar
• Lang R, Reiman R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ. Mol. Mutagen.21, 272–304 (1993).
   PubMed Web of Science ®Google Scholar
• Drevon C, Piccoli C, Montesano R. Mutagenicity assays of estrogenic hormones in mammalian cells. Mutat. Res.89, 83–90 (1981).
   PubMedGoogle Scholar
• Rajah TT, Pento JT. The mutagenic potential of antiestrogens at the HPRT locus in V79 cells. Res. Commun. Mol. Pathol. Pharmacol.89, 85–92 (1995).
   PubMedGoogle Scholar
• Tsutsui T, Suzuki N, Fukuda S et al. 17β-estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. Carcinogenesis8, 1715–1719 (1987).
   PubMedGoogle Scholar
• Tsutsui T, Barrett JC. Neoplastic transformation of cultured mammalian cells by estrogens and estrogen-like chemicals. Environ. Health Perspect.105, 619–324 (1997).
   PubMedGoogle Scholar
• Tsutsui T, Taguchi S, Tanaka Y, Barrett JC. 17β-estradiol, diethylstilbestrol, tamoxifen, toremifene and ICI 164,384 induce morphological transformation and aneuploidy in cultured Syrian hamster embryo cells. Int. J. Cancer70, 188–193 (1997).
   PubMedGoogle Scholar
• Banerjee SH, Banerjee S, Li S A, Li JJ. Cytogenetic changes in renal neoplasms and during estrogen-induced carcinogenesis. In: Hormonal Carcinogenesis. Li JJ, Nandi S, Li SA (Eds). Springer-Verlag, NY, USA, 247–251 (1992).
   Google Scholar
• Banerjee SK, Banerjee S, Li SA, Li JJ. Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. Mutat. Res.311, 191–197 (1994).
   PubMed Web of Science ®Google Scholar
• Tsutsui T, Suzuki N, Maizumi H, Barrett JC. Aneuploidy induction in human fibroblasts: comparison with results in Syrian hamster fibroblasts. Mutat. Res.240, 241–249 (1990).
   PubMedGoogle Scholar
• Hunt PA, Koehler KE, Susiarjo M et al. Bisphenol A exposure causes meiotic aneuploidy in the female mouse. Curr. Biol.13, 546–553 (2003).
   PubMed Web of Science ®Google Scholar
• Sisiarjo M, Hassold TJ, Freeman E, Hunt PA. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. PloS Genet.3(1), 63–70 (2007).
   Google Scholar
• Jones LA, Hajek RA. Effects of estrogenic chemicals on development. Environ. Health Perspect.103, 63–67 (1995).
   PubMed Web of Science ®Google Scholar
• Hajek RA, Pathak S, Boddie AK, Jones LA. Aneuploidy of mouse cervicovaginal epithelium induced by perinatal estrogen treatment. Proc. Am. Assoc. Cancer Res.30, 299 (1989).
   Google Scholar
• Li JJ, Hou X, Banerjee SK et al. Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation. Cancer Res.59, 2340–2346 (1999).
   PubMedGoogle Scholar
• Hodgson AV, Ayala-Torres S, Thompson EB, Liehr JG. Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis19, 2169–2172 (1998).
   PubMed Web of Science ®Google Scholar
• Yared E, McMillan TJ, Martin FL. Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis17(4), 345–352 (2002).
   PubMed Web of Science ®Google Scholar
• Cavalieri EL, Frenkel K, Liehr JG, Rogan EG, Roy D. Estrogens as endogenous genotoxic agents – DNA adducts and mutations. J. Natl Cancer Inst.27, 75–93 (2000).
   Google Scholar
• Martin FL, Patel I, Sozeri O et al. Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. Prostate70, 1586–1599 (2010).
   PubMed Web of Science ®Google Scholar
• Tang YM, Green BL, Chen GF et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African–Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics10, 761–766 (2000).
   PubMedGoogle Scholar
• Bartke A, Doherty P, Steger R et al. Effects of estrogen-induced hyperprolactinemia on endocrine and sexual functions in adult male rats. Neuroendocrinology39, 126–135 (1984).
   PubMedGoogle Scholar
• Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum. Exp. Toxicol.25(7), 395–404 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol. Metab.21(11), 691–698 (2010).
   PubMed Web of Science ®Google Scholar
• Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J. Neuroendocrinol.22(7), 771–777 (2010).
   PubMedGoogle Scholar
• Li J, Ahonen TJ, Alanen K et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res.64(14), 4774–4782 (2004).
   PubMed Web of Science ®Google Scholar
• Tan SH, Dagvadorj A, Shen F et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res.68(1), 236–248 (2008).
   PubMed Web of Science ®Google Scholar
• Ahonen TJ, Härkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology140, 5412–5421 (1999).
   PubMed Web of Science ®Google Scholar
• Prins GS. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate. Endocrinology120(4), 1457–1464 (1987).
   PubMedGoogle Scholar
• Van Coppenolle F, Slomianny C, Carpentier F. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am. J. Physiol. Endocrinol. Metab.280(1), E120–E129 (2001).
   PubMed Web of Science ®Google Scholar
• Gilleran JP, Putz O, DeJong M et al. The role of prolactin in the prostatic inflammatory response to neonatal estrogen. Endocrinology144(5), 2046–2054 (2003).
   PubMed Web of Science ®Google Scholar
• Tam NN, Szeto CY, Freudenberg JM, Fullenkamp AN, Medvedovic M, Ho SM. Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia. Mol. Endocrinol.24(11), 2207–2217 (2010).
   PubMedGoogle Scholar
• Fenner A. Prostate cancer: antagonizing the prolactin receptor prevents tumorigenesis in a transgenic mouse model of prostate cancer. Nat. Rev. Urol.7(11), 591 (2010).
   PubMedGoogle Scholar
• Prins GS, Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology138(5), 1801–1809 (1997).
   PubMed Web of Science ®Google Scholar
• Bianco JJ, McPherson SJ, Wang H, Prins GS, Risbridger GP. Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life. Am. J. Pathol.168, 1869–1878 (2006).
   PubMed Web of Science ®Google Scholar
• Ellem SJ, Wang H, Poutanen M, Rispbridger G. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am. J. Pathol.175, 1187–1199 (2009).
   PubMed Web of Science ®Google Scholar
• Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate44, 19–25 (2000).
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet357, 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature420, 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J. Intern. Med.248, 171–183 (2000).
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol.155, 1985–1992 (1999).
   PubMed Web of Science ®Google Scholar
• Palapattu GS, Sutcliffe S, Bastian PJ et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis26, 1170–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology13, 72–79 (2002).
   PubMed Web of Science ®Google Scholar
• Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am. J. Surg. Pathol.22, 1073–1077 (1998).
   PubMedGoogle Scholar
• Woenckhaus J, Fenic I. Proliferative inflammatory atrophy: a background lesion of prostate cancer? Andrologia40(2), 134–137 (2008).
   PubMed Web of Science ®Google Scholar
• Frenkel K, Wei L, Wei H. 7, 12-Dimethylbenz[a]anthracene induces oxidative DNA modification in vivo. Free Radic. Biol. Med.19, 373–380 (1995).
   PubMedGoogle Scholar
• Elmets CA, Athar M, Tubesing KA et al. Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex. Proc. Natl Acad. Sci. USA95, 14915–14919 (1998).
   PubMed Web of Science ®Google Scholar
• Casale GP, Cheng Z, Liu J et al. Profiles of cytokine mRNAs in the skin and lymph nodes of SENCAR mice treated epicutaneously with dibenzo[a, l]pyrene or dimethylbenz[a]anthracene reveal a direct correlation between carcinogen-induced contact hypersensitivity and epidermal hyperplasia. Mol. Carcinog.27, 125–140 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis CE, Leek R, Harris A et al. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol.57, 747–751 (1995).
   PubMed Web of Science ®Google Scholar
• Chen Z, Malhotra PS, Thomas GR et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res.5, 1369–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Eve BY et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res.6, 2104–2119 (2000).
   PubMed Web of Science ®Google Scholar
• Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer127(7), 1680–1691 (2010).
   PubMed Web of Science ®Google Scholar
• Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006. Int. J. Cancer128(10), 2444–2452 (2010).
   Google Scholar
• Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. Non-steroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol. Biomarkers Prev.19(7), 1696–1708 (2010).
   PubMed Web of Science ®Google Scholar
• Mueller SO, Korach SK. Estrogen receptors and endocrine diseases. Lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol.1, 613–619 (2001).
   PubMedGoogle Scholar
• Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur. Urol.55, 533–542 (2009).
   PubMed Web of Science ®Google Scholar
• Chang WY, Prins GS. Estrogen receptor-β: implications for the prostate gland. Prostate40, 115–124 (1999).
   PubMedGoogle Scholar
• Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell Biochem.91, 491–503 (2004).
   PubMed Web of Science ®Google Scholar
• Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signalling. J. Mol. Endocrinol.39, 183–188 (2007).
   PubMedGoogle Scholar
• Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur. J. Cancer44, 928–936 (2008).
   PubMedGoogle Scholar
• Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol.155, 641–647 (1999).
   PubMed Web of Science ®Google Scholar
• Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol.67, 335–376 (2005).
   PubMed Web of Science ®Google Scholar
• Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol. Metab.20(10), 489–494 (2009).
   Google Scholar
• O’Dowd BF, Nguyen T, Marchese A et al. Discovery of three novel G-protein-coupled receptor genes. Genomics47(2), 310–313 (1998).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate28, 98–106 (1996).
   PubMed Web of Science ®Google Scholar
• Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res.61, 6089–6097 (2001).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate48(4), 285–291 (2001).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the PS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum. Pathol.26(8), 824–828 (1995).
   PubMed Web of Science ®Google Scholar
• Price D, Stein B, Sieber P et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, Phase IIB clinical trial. J. Urol.176, 965–970 (2006).
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of anovel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA93, 5925–5930 (1996).
   PubMed Web of Science ®Google Scholar
• Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor β (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate54, 79–87 (2003).
   PubMed Web of Science ®Google Scholar
• Adams JY, Leav I, Lau KM, Ho SM, Pflueger SM. Expression of estrogen receptor β in the fetal, neonatal, and prepubertal human prostate. Prostate52(1), 69–81 (2002).
   PubMed Web of Science ®Google Scholar
• Hedelin M, Bälter KA, Chang ET et al. Dietary intake of phytoestrogens, estrogen receptor-β polymorphisms and the risk of prostate cancer. Prostate66, 1512–1520 (2006).
   PubMed Web of Science ®Google Scholar
• Leav I, Lau KM, Adams JY et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol.159(1), 79–92 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Leav I, Leung YK et al. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol.164(6), 2003–2012 (2004).
   PubMed Web of Science ®Google Scholar
• Mak P, Leav I, Pursell B. ERB impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell17, 319–332 (2010).
   PubMedGoogle Scholar
• McPherson SJ, Hussain S, Balanathan P et al. Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNF α mediated. Proc. Natl Acad. Sci. USA107(7), 3123–3128 (2010).
   PubMed Web of Science ®Google Scholar
• Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J. Endocrinol.204, 105–114 (2009).
   PubMedGoogle Scholar
• Maggiolini M, Vivacqua A, Fasanella G et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem.279, 27008–27016 (2004).
   PubMed Web of Science ®Google Scholar
• Albanito L, Sisci D, Aquila S et al. EGF induces GPR30 expression in estrogen receptor-negative breast cancer cells. Endocrinology149, 3799–3808 (2008).
   PubMed Web of Science ®Google Scholar
• Vivacqua A, Bonofiglio D, Recchia AG et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol.20, 631–646 (2006).
   PubMed Web of Science ®Google Scholar
• Vivacqua A, Lappano R, De Marco P et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF α in estrogen receptor α-positive cancer cells. Mol. Endocrinol.23, 1815–1826 (2009).
   PubMed Web of Science ®Google Scholar
• Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science307, 1625–1630 (2005).
   PubMed Web of Science ®Google Scholar
• Albanito L, Madeo A, Lappano R et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res.67, 1859–1866 (2007).
   PubMed Web of Science ®Google Scholar
• Vivacqua A, Bonofiglio D, Albanito L et al. 17β-estradiol, genistein and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol. Pharmacol.70, 1414–1423 (2006).
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Brailoiu E, Yerrum S et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res.70, 1184–1194 (2010).
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci.29, 116–123 (2008).
   PubMed Web of Science ®Google Scholar
• Dong S, Terasaka S, Kiyama R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ. Pollut.159(1), 212–218 (2010).
   PubMedGoogle Scholar
• Filardo EJ, Graeber CT, Quinn JA et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinico-pathologic determinants of tumor progression. Clin. Cancer Res.12, 6359–6366 (2006).
   PubMed Web of Science ®Google Scholar
• Arias-Pulido H, Royce M, Gong Y et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res. Treat.123(1), 51–58 (2010).
   PubMed Web of Science ®Google Scholar
• Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17β-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res.70(14), 6036–6046 (2010).
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP et al. Bone marrow-derived mesenchymal stem cells promote breast cancer metastasis. Nature449, 557–563 (2007).
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature432, 332–337 (2004).
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer392–401 (2006).
   PubMedGoogle Scholar
• Chan QKY, Lam HM, Ng CF et al. Activation of GPR30 inhibits growth of prostate cancer cells via sustained activation of Erk1/2, c-jun/c-fos-dependendent upregulation of p21, and induction of G2 cell-cycle arrest. Cell Death Differ.17(9), 1511–1523 (2011).
   Google Scholar
• Zhou HB, Carlson KE, Stossi F et al. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor α selective activity. Bioorg. Med. Chem. Lett.19(1), 108–110 (2009).
   PubMedGoogle Scholar
• Meyers MJ, Sun J, Carlson KE et al. Estrogen receptor-α potency-selective ligands: structure–activity relationship studies of diarylpropionitriles and their acetylene and polar analogs. J. Med. Chem.44(24), 4230–4251 (2001).
   PubMed Web of Science ®Google Scholar
• Neubauer BL, Best KL, Counts DF et al. Raloxifene (LY156758) producesantimetastatic responsesandextends survival in the PAIII rat prostatic adenocarcinoma model. Prostate27, 220–229 (1995).
   PubMedGoogle Scholar
• Kim IY, Seong DH, Kim BC et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen- responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res.62, 3649–3653 (2002).
   PubMed Web of Science ®Google Scholar
• Kim IY, Kim BC, Seong DH et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen- independent human prostate cancer cell lines. Cancer Res.62, 5365–5369 (2002).
   PubMed Web of Science ®Google Scholar
• Neubauer BL, McNulty AM, Chedid M et al. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res.63, 6056–6062 (2003).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol. Cancer Ther.5, 1539–1549 (2006).
   PubMed Web of Science ®Google Scholar
• Chadha MK, Ashraf U, Lawrence D et al. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate68, 1461–1466 (2008).
   PubMedGoogle Scholar
• Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res.62, 1370–1376 (2002).
   PubMed Web of Science ®Google Scholar
• Setlur SR, Mertz KD, Hoshida Y et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst.100, 815–825 (2008).
   PubMedGoogle Scholar
• Bergan RC, Reid E, Myers CE. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res.5(9), 2366–2373 (1999).
   PubMedGoogle Scholar
• Smith MR, Malkowicz SB, Chu F et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter Phase 3 clinical study. J. Urol.179, 152–155 (2008).
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Chu F et al. Toremifene improves lipid profiles in men receiving androgendeprivation therapy for prostate cancer: interim analysis of a multicenter Phase III study. J. Clin. Oncol.26, 1824–1829 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett.288(2), 133–148 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor SE, Patel II, Singh PB et al. Elevated oestrogen receptor splice variant ER αΔ5 expression in tumour-adjacent hormone responsive tissue. Int. J. Environ. Res. Public Health7(11), 3871–3889 (2010).
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr. Cancer61(5), 598–606 (2009).
   PubMed Web of Science ®Google Scholar
• Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res.61, 6777–6782 (2001).
   PubMed Web of Science ®Google Scholar
• Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J. Nutr.135(5), 989–995 (2005).
   PubMed Web of Science ®Google Scholar
• McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rate prostate carcinogenesis by soy isoflavones and by Bowman–Birk inhibitor. Nutr. Cancer57(2), 184–193 (2007).
   PubMed Web of Science ®Google Scholar
• Kumi-Diaka J, Merchant K, Haces A, Hormann V, Johnson M. Genistein–selenium combination induces growth arrest in prostate cancer cells. J. Med. Food13(4), 842–850 (2010).
   PubMedGoogle Scholar
• Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell Biochem.91, 540–552 (2004).
   PubMedGoogle Scholar
• Yamasaki M, Mukai A, Ohba M et al. Genistein induced apoptotic cell death in adult T-cell leukemia cells through estrogen receptors. Biosci. Biotechnol. Biochem.74(10), 2113–2115 (2010).
   PubMed Web of Science ®Google Scholar
• Donzelli A, Braida D, Finardi A, Capurro V, Colleoni M, Sala M. Neuroprotective effects of genistein in mongolian gerbils: estrogen receptor-β involvement. J. Pharmacol. Sci.114(2), 158–167 (2010).
   PubMed Web of Science ®Google Scholar
• Matsumura K, Tanaka T, Kawashima H, Nakatani T. Involvement of the estrogen receptor β in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells. Anticancer Res.28(2A), 709–714 (2008).
   PubMedGoogle Scholar
• Iso T, Watanabe T, Iwamoto T, Shimamoto A, Furuichi Y. DNA damage cuased by bisphenol A and estradiol through estrogenic activity. Biol. Pharm. Bull.29, 206–210 (2006).
   PubMed Web of Science ®Google Scholar
• Allen DL, Mitchner NA, Uveges TE, Nephew KP, Khan S, Ben-Jonathan N. Cell-specific induction of c-fos expression in the pituitary gland by estrogen. Endocrinology138(5), 2128–2135 (1997).
   PubMed Web of Science ®Google Scholar
• Benker G, Jaspers C, Häusler G, Reinwein D. Control of prolactin secretion. Klin. Wochenschr.68(23), 1157–1167 (1990).
   PubMedGoogle Scholar